Candida albicans is the most prevalent fungal species of the human microbiota.Many nosocomial Candida albicans infections are polymicrobial.The interaction between Candida albicans and other bacteria can be synergistic,antagonistic,and one side benefit,which cause damage of host in different way.Co-infections influence the biochemistry and polybiofilm among pathogenic microorganisms,and then change the drug resistance,response host immunity,and virulence.This makes co-infections more difficult to be cured than mono-infections.The coinfection of Candida albicans and other bacteria has a high incidence rate and mortality rate,which is a serious problem faced by clinicians.The mechanism of interaction between Candida albicans and other bacteria has an important significance in diagnosis and co-infection treatment.In this paper,the research progress of interaction between Candida albicans and Staphylococcus aureus,Pseudomonas aeruginosa,Streptococcus mutans,as well as Lactobacilli was reviewed.

Lung cancer is the leading cause of cancer death in the world today, and adenocarcinoma is the most common histopathological type of lung cancer. In May 2021, World Health Organization (WHO) released the 5th edition of the WHO classification of thoracic tumors, which classifies invasive non-mucinous adenocarcinoma (INMA) into lepidic adenocarcinoma, acinar adenocarcinoma, papillary adenocarcinoma, solid adenocarcinoma, and micropapillary adenocarcinoma based on its histological characteristics. These five pathological subtypes differ in clinical features, treatment and prognosis. A complete understanding of the characteristics of these subtypes is essential for the clinical diagnosis, treatment options, and prognosis predictions of patients with lung adenocarcinoma, including recurrence and progression. This article will review the grading system, morphology, imaging prediction, lymph node metastasis, surgery, chemotherapy, targeted therapy and immunotherapy of different pathological subtypes of INMA.
.
Humans ; Lung Neoplasms/pathology* ; Adenocarcinoma of Lung/pathology* ; Adenocarcinoma/pathology* ; Prognosis ; Lymphatic Metastasis ; Neoplasm Staging ; Retrospective Studies